Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

Elixir Medical Corp. DESolve 100 CE mark
Feature

May 13, 2014 — Elixir Medical Corp. received European CE mark approval for its DESolve 100 Novolimus-eluting Bioresorbab ...

Home May 13, 2014
Home
Feature

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the ...

Home April 16, 2014
Home
Videos | Stents Bioresorbable

Bioresorbable stent technology was one of the big interventional technologies discussed at the American College of ...

Home April 03, 2014
Home
Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent
Feature

March 31, 2014 — Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo ...

Home March 31, 2014
Home
News

March 12, 2014 — Micell Technologies Inc. announced that imaging and clinical results from the DESSOLVE I and DESSOLVE ...

Home March 12, 2014
Home
News

January 23, 2014 – Six-month results of the ESPRIT trial suggest a bioresorbable drug-eluting scaffold is effective in ...

Home January 23, 2014
Home
News
January 23, 2014 — An implant of the ReZolve2 bioresorbable scaffold was transmitted live via satellite at the ...
Home January 23, 2014
Home
News
January 22, 2014 — The first commercial implant of Elixir Medical’s CE Mark-approved DESolve Novolimus Eluting Coronary ...
Home January 22, 2014
Home
cath lab stents bioresorbable amaranth fortitude scaffold
Feature
January 14, 2014 — Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp. The ...
Home January 14, 2014
Home
ACC, iPad cardiology apps
Feature | Dave Fornell
DAIC readers chose the following stories as the most popular content in 2013, based on website analytics. The list is ...
Home January 03, 2014
Home
stents bioresorbable cath lab intravascular imaging clinical trial study abbott
Feature
November 7, 2013 — The Cardiovascular Research Foundation (CRF) and the Uppsala Clinical Research Center (UCR) of ...
Home November 07, 2013
Home
Feature
November 1, 2013 — A study found that both drug-eluting stents (DES) with biocompatible polymers and DES with ...
Home November 01, 2013
Home
News
October 31, 2013 — Amaranth Medical presented positive six-month angiographic results from its first-in-human study of ...
Home October 31, 2013
Home
News

October 23, 2013 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to ...

Home October 23, 2013
Home
News

October 8, 2013 — Micell Technologies Inc. announced that a peer reviewed article discussing imaging and clinical ...

Home October 08, 2013
Home
Subscribe Now